ArticleMedicine2026
Pediatric primary ciliary dyskinesia with rare genetic variants: Synonymous RSPH4A and potential NFE2L2 modifier of DNAH9 phenotype - 2-case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePrimary ciliary dyskinesia (PCD) is easily underdiagnosed in children without laterality defects. We report 2 pediatric cases of PCD, highlighting a candidate pathogenic synonymous RSPH4A variant and a possible modifier effect of NFE2L2 on DNAH9-related disease. PATIENT CONCERNS: Case 1: a 5-year-old girl presented with chronic wet cough and recurrent pulmonary consolidations. Case 2: a 5-year-old boy presented with chronic wet cough, recurrent wheeze, and rhinosinusitis. DIAGNOSES: Case 1 had a normal immune work-up and underwent trio whole-exome sequencing (WES), which identified compound heterozygous RSPH4A variants (c.1391G>A and the synonymous c.1764G>T variant with a high predicted splicing impact), supporting a diagnosis of PCD. Case 2 had markedly elevated immunoglobulin E and an obstructive ventilatory defect; WES identified compound heterozygous DNAH9 variants together with an NFE2L2 exon 2-5 deletion, consistent with PCD with enhanced type 2 inflammation.
interventionsCase 1 received antibiotic therapy. Case 2 was treated with antibiotics, bronchodilators, and inhaled corticosteroids. OUTCOMES: Case 1 improved after antibiotic therapy, and no bronchiectasis was detected during follow-up. Case 2 also improved clinically, although moderate airflow obstruction persisted. LESSONS: These cases suggest that synonymous variants with strong splicing predictions in PCD genes may be pathogenic and that NFE2L2-related pathways may modify DNAH9-associated PCD severity. Early WES may facilitate diagnosis in children with chronic wet cough and recurrent infections, even without laterality defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.